Genotropin New Zealand - English - Medsafe (Medicines Safety Authority)

genotropin

pfizer new zealand limited - somatropin 5.8mg equivalent to 5 mg somatropin (after reconstitution) - powder for injection - 5 mg - active: somatropin 5.8mg equivalent to 5 mg somatropin (after reconstitution) excipient: dibasic sodium phosphate glycine mannitol monobasic sodium phosphate mannitol metacresol water for injection - adults replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in two different dynamic tests for growth hormone deficiency. patients must also fulfill the following criteria. childhood onset: patients, who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with genotropin miniquick is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. prader-willi syndrome, for improvement of body composition.

Saizen 8 New Zealand - English - Medsafe (Medicines Safety Authority)

saizen 8

pharmacy retailing (nz) ltd t/a healthcare logistics - somatropin 8.8mg ((includes 0.8 mg overfill)) - injection with diluent - 8 mg - active: somatropin 8.8mg ((includes 0.8 mg overfill)) excipient: phosphoric acid sodium hydroxide sucrose metacresol water for injection - saizen is indicated for: 1. growth failure in children due to human growth hormone deficiency. 2. growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis. 3.saizen is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfil the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. 4. growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

Norditropin NordiFlex 15 mg/1.5 ml solution for injection in pre-filled pen Ireland - English - HPRA (Health Products Regulatory Authority)

norditropin nordiflex 15 mg/1.5 ml solution for injection in pre-filled pen

novo nordisk a/s - somatropin - solution for injection in pre-filled pen - 15mg/1.5ml micromole(s) - somatropin and somatropin agonists; somatropin

Norditropin NordiFlex 5 mg/1.5 ml solution for injection in pre-filled pen Ireland - English - HPRA (Health Products Regulatory Authority)

norditropin nordiflex 5 mg/1.5 ml solution for injection in pre-filled pen

novo nordisk a/s - somatropin - solution for injection in pre-filled pen - 5mg/1.5ml micromole(s) - somatropin and somatropin agonists; somatropin

Norditropin SimpleXx 5 mg/1.5 ml, solution for injection in cartridge Ireland - English - HPRA (Health Products Regulatory Authority)

norditropin simplexx 5 mg/1.5 ml, solution for injection in cartridge

novo nordisk a/s - somatropin - solution for injection in cartridge - 5mg/1.5ml - somatropin and somatropin agonists; somatropin

Norditropin SimpleXx 15 mg/1.5 ml, solution for injection in cartridge Ireland - English - HPRA (Health Products Regulatory Authority)

norditropin simplexx 15 mg/1.5 ml, solution for injection in cartridge

novo nordisk a/s - somatropin - solution for injection in cartridge - 15mg/1.5ml - somatropin and somatropin agonists; somatropin

Somatropin Biopartners European Union - English - EMA (European Medicines Agency)

somatropin biopartners

biopartners gmbh - somatropin - growth - pituitary and hypothalamic hormones and analogues, somatropin and somatropin agonists - somatropin biopartners is indicated for the replacement therapy of endogenous growth hormone in adults with childhood- or adult-onset growth-hormone deficiency (ghd).adult-onset: patients with ghd in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone excluding prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a ghd.childhood-onset: in patients with childhood-onset isolated ghd (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be performed after completion of growth, except for those having low insulin-like-growth-factor-i (igf-i) concentrations (< -2 standard-deviation score (sds)), who may be considered for one test. the cut-off point of the dynamic test should be strict.

SAIZEN 8.8MG (5.83MG/ML) POWDER FOR SOLUTION Canada - English - Health Canada

saizen 8.8mg (5.83mg/ml) powder for solution

emd serono, a division of emd inc., canada - somatropin - powder for solution - 8.8mg - somatropin 8.8mg - pituitary

NUTROPIN - KIT PWS(5MG) & LIQ(10ML) IM SC Canada - English - Health Canada

nutropin - kit pws(5mg) & liq(10ml) im sc

hoffmann-la roche limited - somatropin; water - kit - 5mg; 10ml - somatropin 5mg; water 10ml - pituitary

NUTROPIN AQ - SC 5MG/ML LIQUID Canada - English - Health Canada

nutropin aq - sc 5mg/ml liquid

hoffmann-la roche limited - somatropin - liquid - 5mg - somatropin 5mg - pituitary